Skip to main content
Caplight Logo









PulseSight Therapeutics

PulseSight Therapeutics

Private
ParisHealthcare & Life Scienceshttps://pulsesight.com/

Last Round

Series A

Feb 13, 2025

Total Funding Raised

$54.14M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

PulseSight Therapeutics is a biotechnology company that develops non-viral gene therapies for the treatment of retinal diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

non-viral gene therapyelectro-transfectionage-related macular degenerationAMDgeographic atrophyGAocular gene therapyretinal diseasesgene therapy deliverylong-acting therapyciliary muscle deliverysustained protein expressionDNA plasmidsophthalmologydrug delivery platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PulseSight Therapeutics Comparables

Compare PulseSight Therapeutics with similar companies based on industry and business-model similarity.

PulseSight Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Complement Therapeutics
82%
Atsena Therapeutics
79%
Eli Lilly and Company
78%

PulseSight Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AFeb 13, 2025
SeedFeb 28, 2024
Series B ExtensionAug 4, 2021
Series BJan 8, 2020
Series ASep 16, 2016
VC Round
Apr 11, 2013

Key People

Founding team and executive leadership

Judith Greciet

Chief Executive Officer

Executive Team

Thierry Bordet

CSO COO

Executive Team

PulseSight Therapeutics Investors

Notable investors and investment history

PulseSight Therapeutics investors
InvestorRounds
Korea Investment PartnersSeed, Series B Extension
Inserm TransfertSeries A, Seed, Series B, VC Round
Pontifax Venture CapitalSeries A, Series B
+ND CapitalSeed
Pureos BioventuresSeries A, Series B, Seed
Boehringer Ingelheim Venture FundSeries A, VC Round, Series B
KaristaSeries A, Seed, Series B, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors increased 43% MoM.

  • Apr 24, 2026

    Monthly visitors grew 50% MoM.

PulseSight Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PulseSight Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PulseSight Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range10
Year Founded2008
Last FundingFeb 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?